Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding Using Sublingual Misoprostol

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2012 by Mahidol University.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Mahidol University
ClinicalTrials.gov Identifier:
First received: December 11, 2012
Last updated: January 4, 2013
Last verified: September 2012

Abnormal uterine bleeding is common in Thai women. Fractional curettage is an diagnostic procedure of this condition. Traditionally, fractional curettage is performed under local anesthesia such as paracervical nerve block or intravenous meperidine.

Cervical dilatation using "metal cervical dilator" is a common method prior to perform fractional curettage. However, complication from this procedure can be occurred frequently, for example, uterine perforation, false tract formation and laceration of cervix.

Misoprostol is a prostaglandin E1 analogue which is commonly used in obstetrics and gynecology. Misoprostol transforms cervical component causing cervical ripening. This is very helpful for transcervical procedure because cervical dilatation is usually omitted. It can be prescribed in many route and sublingual route is the most effectiveness. Moreover, WHO supports the use of misoprostol in obstetrics and gynecology practice.

The hypothesis of this study is that "Misoprostol 200 micrograms sublingually is effective for cervical ripening before performing fractional curettage in patients with abnormal uterine bleeding" Double blind randomised controlled trial was performed using 26 patients in each group.

Condition Intervention
Abnormal Uterine Bleeding Unrelated to Menstrual Cycle
Drug: Misoprostol
Drug: Vitamin B6

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding (AUB) Using Sublingual Misoprostol 200 Mcg: A Randomized, Double Blind, Placebo-controlled Trial

Resource links provided by NLM:

Further study details as provided by Mahidol University:

Primary Outcome Measures:
  • efficacy of 200 microgram Misoprostol for cervical ripening prior to performing fractional curettage in patients with abnormal uterine bleeding [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
    an efficacy of sublingual misoprostol in this study was dilatation of uterine cervix which was measured by a diameter of MVA cannula in millimeters.

Estimated Enrollment: 52
Study Start Date: November 2012
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Misoprostol
200 mcg Misoprostol SL 1 hour prior to fractional curettage
Drug: Misoprostol
Other Name: Cytotec
Placebo Comparator: Vitamin B6
100 mg Vitamin B6 SL 1 hr prior to fractional curettage
Drug: Vitamin B6
Other Name: Besix


Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • thai women at the age over 35 years old
  • presenting with abnormal uterine bleeding and have a plan to perform fractional curettage

Exclusion Criteria:

  • uterine anomalies
  • pregnancy
  • pelvic inflammatory disease
  • uncontrolled medical or psychological conditions
  • known cases of gynecological diseases such as gynecological malignancies, abnormal pap smear
  • Prostaglandin allergy
  • Contraindicate to prostaglandin: asthma, mitral valve stenosis, glaucoma, sickle cell anemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01762319

Contact: Korakot Sirimai, Dr. (66)81-6140655 ksirimai@hotmail.com

Faculty of Medicine Siriraj Hospital Mahidol University Recruiting
Bangkok, Thailand, 10700
Contact: Korakot Sirimai, Dr.    (66)81-6140655    ksirimai@hotmail.com   
Principal Investigator: Korakot Sirimai, Dr.         
Sub-Investigator: Tripop Lertbunnaphong, Dr.         
Sponsors and Collaborators
Mahidol University
Principal Investigator: Korakot Sirimai, MD Mahidol University
  More Information


Responsible Party: Mahidol University
ClinicalTrials.gov Identifier: NCT01762319     History of Changes
Other Study ID Numbers: SIOGMVA002 
Study First Received: December 11, 2012
Last Updated: January 4, 2013
Health Authority: Thailand: Ethical Committee

Additional relevant MeSH terms:
Uterine Hemorrhage
Genital Diseases, Female
Pathologic Processes
Uterine Diseases
Vitamin B 6
Vitamin B Complex
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Anti-Ulcer Agents
Gastrointestinal Agents
Growth Substances
Physiological Effects of Drugs
Reproductive Control Agents

ClinicalTrials.gov processed this record on May 26, 2016